IMVT

Immunovant
IMVT

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$2.65B
EV
$2.05B
Shares Outstanding
176.83M
Beta
0.66

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
$39.46
P/E 2026E
-
P/Revenue 2026E
277.31x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Immunovant, Inc.

gainify
IMVT

Immunovant, Inc.

IMVT

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor fo...

Sector

Healthcare

Industry

Biotechnology

CEO

Salzmann, Peter

Employees

362

IPO Date

2019-06-21

Headquarters

320 West 37th Street, 6th Floor, New York, New York, 10018, United States

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.